Want to see AU:NTI full AI Analyst Report?
NTI Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume153.13K
Average Volume (3M)3.74M
Market Cap
AU$23.43M
Enterprise ValueAU$16.06
Total Cash (Recent Filing)AU$2.39M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,616,070,000
10 Day Avg. Volume4,942,222
30 Day Avg. Volume3,735,571
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)27.08
Price to Sales (P/S)0.00
P/FCF Ratio-3.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet removes interest expense and near-term leverage pressure, giving management greater flexibility while the company develops its therapies. This reduces financing risk relative to a similarly loss-making biotech carrying material borrowings, although it does not eliminate funding needs.
Improving Free Cash FlowThe substantial reduction in annual free-cash-flow burn indicates some improvement in cash management or spending intensity in the latest period. If maintained, a lower burn rate could extend available resources and reduce the frequency or size of external funding required.
Reported EPS ImprovementReported EPS growth provides evidence of improvement in the per-share earnings measure despite the company remaining loss-making. Sustained progress could support operating leverage over time, though its durability remains unproven because revenue has not yet become recurring.
Bears Say
Revenue Has Fallen To ZeroThe collapse from approximately 2.44M of revenue to zero shows that commercial sales are not yet stable or recurring. Without dependable revenue, the company cannot demonstrate product-market traction or support its operating cost base through internally generated sales.
Persistent Cash BurnPersistent negative operating and free cash flow means the business consumes cash rather than funding operations internally. Even with the latest improvement, continued sizable outflows imply ongoing dependence on external funding, which can constrain development plans and shareholder value.
Shrinking Equity And AssetsThe sharp contraction in equity and total assets indicates that accumulated losses and dilution have materially reduced the financial cushion. A smaller capital base leaves less capacity to absorb setbacks, sustain research programs, or fund operations while revenue remains absent.
Neurotech International News
NTI FAQ
What was Neurotech International Ltd.’s price range in the past 12 months?
Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Neurotech International Ltd.’s market cap?
Neurotech International Ltd.’s market cap is AU$23.43M.
When is Neurotech International Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Neurotech International Ltd.’s earnings last quarter?
Currently, no data Available
Is Neurotech International Ltd. overvalued?
According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued.
Does Neurotech International Ltd. pay dividends?
Neurotech International Ltd. does not currently pay dividends.
What is Neurotech International Ltd.’s EPS estimate?
Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurotech International Ltd. have?
Neurotech International Ltd. has 1,616,070,000 shares outstanding.
What happened to Neurotech International Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neurotech International Ltd.?
Currently, no hedge funds are holding shares in AU:NTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurotech International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NTI Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neurotech International Ltd.
Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and commercializing its Mente platform, a technological system designed to monitor and facilitate home-based therapies. This includes its Mente Autism product, specifically aimed at the diagnosis and treatment of autism spectrum disorder. Additionally, Neurotech actively undertakes various medical research projects and engineers new technological instruments. The company was established in 2016 and maintains its headquarters in Nedlands, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―